Our Principal, Ms. Yolanda Wang, was invited by the Hong Kong Productivity Council to be one of the panelists at the Hong Kong Patent Landscape Report Launching Ceremony last Thursday. Yolanda, alongside other distinguished panelists, shared their insights on Hong Kong’s capabilities and the opportunities that arise from emerging trends in innovations and patent protection within the city.



Our Past Events

Recommended Insights

Twice the Trouble: Unraveling a Single Case of Dual Patent and Trademark Infringement

9 January 2024
Can a rights holder sue the same infringer separately based on one single infringing act that infringes both trademark and patent rights? An interesting case this year from China’s Supreme People’s Court that addresses this specific issue ((2023)最高法知民终235号). Beijing Run De Hong Tu Technology Development Co., Ltd. (“Run De Hong Tu”) sued an individual named […]

CNIPA Releases Interim Measures for the Amended Chinese Patent Law Going Into Effect June 1, 2021

28 May 2021
Breaking News! We finally have more details about the new Chinese Patent Law which will go into effect on June 1, 2021. The full set of measure can be found at this link. Below are some pertinent points. No Implementation Rules . . . . Yet The new Implementation Rules will not be available by […]

From Faces to Football Fields: How Applying AI Models to Different Application Fields Can Prove Inventive in China

21 October 2025
As AI models become versatile and adaptable across multiple contexts and industries, questions about inventive step sit at the heart of patent examination in China. The 2023 Patent Examination Guidelines (hereinafter referred to as 'the Guidelines') included several sessions dedicated to explaining how inventive step should be examined for AI-related inventions, featuring examples related to […]

Compositions Limited by Use: A Cautionary Tale

26 October 2022
Section 4.2.3, Part II Chapter 10 of the CNIPA’s Examination Guidelines (“Guidelines”) stipulates that if the specification only discloses one property or use of a composition, the composition claim shall be drafted as a “composition limited by the function or the use”. Furthermore, it specifically states that “most pharmaceutical claims shall be drafted as claims […]
Top crossarrow-right